TIFFEN,$8,1A,Lens,Skylight,Filter,Camera,/Apostolos414422.html,Electronics , Camera Photo , Accessories,37MM,for,castleevents.com $8 TIFFEN 37MM 1A Skylight Filter for Camera Lens Electronics Camera Photo Accessories TIFFEN 37MM 1A Skylight for Lens Camera Filter Fixed price for sale $8 TIFFEN 37MM 1A Skylight Filter for Camera Lens Electronics Camera Photo Accessories TIFFEN,$8,1A,Lens,Skylight,Filter,Camera,/Apostolos414422.html,Electronics , Camera Photo , Accessories,37MM,for,castleevents.com TIFFEN 37MM 1A Skylight for Lens Camera Filter Fixed price for sale

TIFFEN Be super welcome 37MM 1A Skylight for Lens Camera Filter Fixed price sale

TIFFEN 37MM 1A Skylight Filter for Camera Lens

$8

TIFFEN 37MM 1A Skylight Filter for Camera Lens

|||

Product description

Size:37mm  |  Pattern Name:Filter

Safeguard your lens and absorb UV light. Film and video are more sensitive to UV light than our eyes are. This often shows up as a bluish cast in images, especially shots from high altitudes and long distances, particularly over water. The pink cast of the filter gives a slight warming effect for more pleasing images. Tiffen filters are manufactured using ColorCore technology, a closely guarded proprietary process that entails permanently laminating the filter material in between two pieces of optical glass that are ground flat to tolerances of a ten-thousandth of an inch, then mounting them in precision metal rings. The ColorCore process allows us to control the color and density of Tiffen filters, and the characteristics of special effects filters with much greater accuracy than typical dyed-in-the-mass filters, which usually exhibit color and density .

TIFFEN 37MM 1A Skylight Filter for Camera Lens

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA